Global Hemophilia Market to Reach $23.46 Billion by 2035 as Gene Therapy Grows 12.5%
Updated
Updated · Precedence Research · May 15
Global Hemophilia Market to Reach $23.46 Billion by 2035 as Gene Therapy Grows 12.5%
1 articles · Updated · Precedence Research · May 15
$23.46 billion is the projected size of the global hemophilia market by 2035, up from $13.31 billion in 2026, implying a 6.5% annual growth rate.
Rising diagnosis rates, wider use of advanced prophylactic care and growing adoption of non-factor replacement therapies are driving demand, while AI tools are increasingly used for diagnosis, risk prediction and treatment planning.
gene therapy is forecast to be the fastest-growing treatment segment at a 12.5% CAGR, even as replacement therapy held the largest 2025 revenue share at 50%; subcutaneous delivery is also set to outpace IV growth.
North America led the market with a 42% share in 2025, but Asia-Pacific is expected to expand fastest at a 9.5% CAGR as healthcare spending, awareness and access to specialized care improve.
How is AI changing the daily reality of hemophilia care beyond just market forecasts?
As treatment costs soar, is the innovation boom widening the hemophilia care gap between nations?
Why are multi-million dollar, approved gene therapies for hemophilia being withdrawn from the market?